Uncategorized
(MOST) Finalist in the 2014 NC Tech Awards, New Media/Digital Technology
The Company’s Groundbreaking Mobile App Development Technology and Customer Successes Have Qualified MobileSmith as a Finalist in North Carolina’s Prestigious Technology Awards Program
RALEIGH, NC–(Oct 29, 2014) – MobileSmith (OTCBB: MOST) has been nominated as a finalist in North Carolina’s statewide technology awards program, in the New Media/Digital Technology category. The finalists were recently announced by the North Carolina Technology Association (NCTA).
MobileSmith’s flagship product, the MobileSmith app development platform, empowers non-programmers to rapidly create, launch and manage custom, native mobile apps for iPhone, iPad, and Android smartphones. MobileSmith’s customers include U.S. Navy, Wake Forest Baptist Medical Center, UNC Rex Health, Robert Wood Johnson University Hospital, Civitas Media, Customized Communications, and many other healthcare, media, and government organizations.
“We are thrilled to be nominated for this prestigious award,” said Robert Hancock, MobileSmith VP of Sales. “As an active member of NCTA, MobileSmith is committed to advancing the innovation in the Research Triangle tech community. Our multiple customers and their award-winning apps can attest to that.”
MobileSmith (OTCBB: MOST) is a complete cloud solution for enterprise mobility and a powerful online platform that allows non-programmers to easily prototype, deploy, and manage native applications for iOS and Android smartphones and iPad tablets without writing a line of code. MobileSmith clients can manage each app from a powerful, dedicated CMS; securely integrate their data sources, and take advantage of proximity beacon technology via MobileSmith/Gimbal integration.
Contact:
Janna Badalian
Janna.badalian@mobilesmith.com
919-237-4210
(FBCD) and COCO-AMO in Discussion With Distributors About Purchasing 3,500 Units
FBC and COCO-AMO Expanding Distribution With Partner Based on Retail Sales
NEW YORK, NY–(Oct 29, 2014) – FBC Holding, Inc. (PINKSHEETS: FBCD) (“FBC” or the “Company”) an international product development company primarily focused on license/creation management and product sales/distribution through DRTV, announced that the company is in discussions with multiple distributors in the US to purchase COCO-AMO products.
“We are building off of the recent successful launch of the COCO-AMO product line, at retail stores and our internet blogging launch strategy. Having impressive retail sales with just one of our products — LOVE – Leave in Conditioner, our distribution partner is considering placing an order for all three products and have the ability to offer their customers a collection,” said Mr. Frank Russo, Chief Executive Officer of FBC Holding, Inc. “Being able to provide our customer base — Hydrate — promotes Moisturizing and Pure – a Sulfate-Free Shampoos, is very exciting and we are going to support our customers as they experience the benefits of using our products.”
Darin Braun, Founder and President of COCO-AMO, said, “COCO-AMO is starting from a small base in the market place but we are already getting interest from ‘Major Retailers’, which means that buyers are starting to hear the buzz about our brand. We are looking to expand our product offerings, most likely in 2015, allowing the retailer to dedicate even more selling space to their consumers that will be raving about the results they are getting from our products. We are just about to receive 7,000 units from our PO and now we might have an order for 3,500 units — that is just crazy but I LOVE it.”
“We continue to build out our web presence through our site, COCO-AMO.com and we continue to receive orders daily. Understanding that we are in a competitive multi-billion dollar Health & Beauty industry, we’ll continue to mix it up, expand our grassroots following and provide products the consumer can see benefits from during use,” said Mr. Russo.
About FBC Interactive Division
FBC Holding’s Interactive Division markets innovative products generally incorporating new proprietary technologies. FBC Interactive, leverages Direct Response Television (DRTV) formats to advertise, market and distribute its products; gaining retail footholds in various markets. FBC Interactive’s market place is diverse, with a primary focus and expertise in toy and entertainment, consumer and health care, products and brands.
About FBC Holding, Inc.
FBC Holdings develops and markets innovative products using a ‘new proprietary’ technology whereby buttons, switches, wires and other electrical components can be printed on nearly any media. Management is experienced in Direct to Consumer Marketing (design, manufacture and market creative products leveraging cutting edge technology). FBC’s market is diverse, covering consumer products, health care related products, and, toy and entertainment products.
Safe Harbor
This news release contains forward-looking statements. Forward-looking statements are statements which relate to future events. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results. Readers are referred to the sections entitled “Risk Factors” in the Company’s periodic filings with the United States Securities and Exchange Commission, which can be viewed at http://www.SEC.gov. For all details regarding working interests in all of FBC Holding’s interest, and/or any previous news releases, go to OTC Markets website. You should independently investigate and fully understand all risks before making investment decisions.
Related Links:
http://finance.yahoo.com/news/fbc-holding-positioned-rapid-growth-142935672.html
http://finance.yahoo.com/news/fbc-interactives-direct-response-marketing-140000170.html
For investor relations,
FBC Holding, Inc.
Email Contact
(MHCC) Reports Record Third Quarter Revenue
Full Financial Results to Be Announced in Mid-November
GARDEN CITY, NY–(October 29, 2014) – Millennium Healthcare Inc. (OTCQB: MHCC) today announced that revenues for the three months ended September 30, 2014 are expected to be in excess of $6.0 million. This represents significant growth compared with revenue of $490,000 for the comparable 2013 period, and was largely the result of the initial roll out of the Company’s medical device distribution model. During the quarter Millennium Healthcare began the commercial introduction of its first two distributed medical device products, namely VasoScan™, a cardiovascular diagnostic assessment test, and OralCDx™, a non-invasive brush biopsy kit for oral cancer. Millennium intends to continue its model and mission of evaluating early detection and diagnostic devices and continually looks to add and provide additional products to its medical device lines available for distribution.
Commenting on the quarter, David Perry, chief operating officer, said, “Following successful beta testing in June, we began the initial roll out of the VasoScan and OralCDx products to a small portion of our current network of approximately 1,300 primary care physician offices located along the U.S. East Coast. Physician acceptance, measured by utilization as well as reorder rates, was well above our initial expectations so early in the launch process; and we are extremely pleased with the recognition by our early customers of the role these products can play in preventive care and in medical practice economics. We look forward to continuing a managed introduction of these products via our direct sales force and, in time, via sub-distributor partners with the ultimate goal of nationwide coverage.”
Dominick Sartorio, chief executive officer added, “We are excited to continue the commercialization of our device business and to report to our investors on the progress we have made. We believe our third quarter revenue represents the beginning of a significant growth trend for our business, and given our current commitments, we anticipate being able to report significant quarterly revenue for the fourth quarter as well. We believe the industry trend toward early detection diagnostics, combined with our distribution model, highly experienced leadership team, and our exclusive agreements with suppliers are the driving contributors to our current and future success.”
Millennium Healthcare expects to report full financial results for the third quarter, and to hold its first quarterly investor conference call in mid-November.
About Millennium Healthcare Inc.
Millennium Healthcare Inc., through its wholly owned operating subsidiaries, provides primary care physician practices, physician groups and healthcare facilities of all sizes with cutting-edge medical devices focused primarily on preventive care through early detection. The Company also provides advanced billing and coding services, and practice development and management services.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains certain statements that may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. Because they are forward-looking, they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
COMPANY CONTACT
Millennium Healthcare Inc.
Joe Giamichael
516-628-5500
jgiamichael@millenniumhcs.com
INVESTOR CONTACT
LHA
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
(AMEH) Launches Apollo Palliative Services
GLENDALE, Calif., Oct. 29, 2014 — Apollo Medical Holdings, Inc. (ApolloMed) (OTC-QB: AMEH), an integrated physician-centric healthcare delivery company, today announced the launch of a new subsidiary, Apollo Palliative Services (APS), with the acquisition of majority stakes in both a hospice agency and a home health company. In conjunction, the Company appointed Liviu Chindris, M.D., as President of APS.
APS will serve as a single source for hospice, palliative care and home health services for ApolloMed’s health plan, hospital and IPA clients in addition to its own subsidiaries and affiliated medical groups: ApolloMed ACO, Maverick Medical Group, AKM Medical Group, ApolloMed Care Clinics and ApolloMed Hospitalists. The hospice agency serves three counties in Southern California, with an average daily census of 40-60 patients, while the home health agency services three counties in California with an average daily census of 100-140.
The hospice division of APS will serve terminally ill patients and their families through the use of an interdisciplinary team. Depending on their needs, each hospice patient and their family is assigned a team comprised of a physician, nurse, home health aide, medical social worker, chaplain, dietary counselor and bereavement coordinator. Hospice and palliative care services are provided in the patient’s home, assisted living/nursing home, or in a hospital. The home health division will provide direct home skilled nursing and therapy services, as well as specialty programs such as disease management education, nutrition and help with daily living activities.
ApolloMed believes that several factors will contribute to the growth of its hospice and home health business: aging demographics, recognition that in-home services are significantly more cost-effective than institutional care, medical and technological advances that allow more healthcare procedures and monitoring to be provided at home and the benefits of recuperating from an illness or receiving care for a chronic condition in one’s own home.
“I am very excited to join the management team of ApolloMed as we launch Apollo Palliative Services,” stated Dr. Chindris. “We understand the benefits of hospice, palliative care and home health services for patients and their families and our goal is to make APS one of the leading providers in Southern California.”
“The addition of hospice and home health services will enhance our integrated care model and provide a good platform for the expansion of APS. We believe that as an efficient operator of integrated healthcare delivery, we are favorably positioned to benefit from current industry trends,” stated Warren Hosseinion, M.D., Chief Executive Officer of Apollo Medical Holdings.
“We are also very pleased to have Dr. Chindris, one of the earliest physicians to join HealthCare Partners, as a member of the ApolloMed team. His wealth of knowledge and experience will be a tremendous asset as we continue to grow ApolloMed’s business and expand the services that we provide.”
Dr. Chindris earned his M.D. from the University of Medicine and Pharmacy in Cluj, Romania and completed an internship and residency in internal medicine at Brooklyn Hospital in Brooklyn, New York and Mercy Hospital in Buffalo, New York. He has held memberships in the American College of Physicians and the American Academy of Hospice and Palliative Medicine. He is fluent in Romanian, French, Italian, Spanish and English. Dr. Chindris was a Senior Partner at HealthCare Partners before it was acquired by DaVita in 2012.
About Apollo Medical Holdings, Inc.
ApolloMed is a leading integrated physician-centric healthcare delivery company commited to providing exceptional multi-disciplinary care in the communities it serves. ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare delivery platform comprised of six affiliated and complementary physician groups: ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group (Independent Physician Association), AKM Medical Group (IPA), ApolloMed Care Clinics and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care. For more information, please visit www.apollomed.net.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management’s view of future expectations, plans and prospects for Apollo Medical Holdings, Inc. (“the Company”). In particular, when used in the preceding discussion, where we refer to quarter over quarter revenue growth targeted for the remainder of 2014 and the words “predicts,” “believes,” “expects,” “intends,” “seeks,” “estimates,” “plans,” “anticipates,” and similar conditional expressions or future or conditional verbs such as “will,” “may,” “might,” “should,” “would” and “could” are intended to identify forward-looking statements. In addition, our representatives may from time to time make oral forward-looking statements. Any such statements, other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company’s management. Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance or achievements of the Company, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in the relevant forward-looking statement as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included herein are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended January 31, 2014 and in any of the Company’s other subsequent Securities and Exchange Commission filings.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT
The Ruth Group
David Burke
646-536-7009 or via email at dburke@theruthgroup.com
(GRAS) Enters Into a Preliminary Agreement With SoFran
WEST PALM BEACH, FL–(Oct 29, 2014) – Greenfield Farms Food, Inc. (“Greenfield” or the “Company”) (OTC: GRAS) and its wholly-owned subsidiary Carmela’s Pizzeria (“Carmela’s”) announced today that they have entered into a preliminary agreement with SoFran, LLC. (“SoFran”) to develop the formation and roll-out of a nationwide franchising program. Terms of the agreement include retaining SoFran to develop a detailed master franchise agreement including all legal and compliance documentation and to evaluate each of the three existing locations in Ohio to determine the best model for the purposes of franchising on a nationwide scale.
The management of Carmela’s has built a proven and replicable model that can be successfully launched in multiple regions of the United States. The agreement with SoFran gives Carmela’s the opportunity to develop and execute a strategy that allows for a timely launch of an appropriate dining concept that’s well suited for future franchisees.
SoFran has an extensive track record in building brands and networks of franchises across the United States. Wayne Mills, President of SoFran commented: “Carmela’s Pizzeria has built a great concept that has the potential to be a recognizable brand throughout the Country. We look forward to working with Carmela’s to launch a successful franchise program.”
SoFran’s management team has over 100 years combined franchising and investment banking experience. SoFran has worked with companies of all sizes and has successfully guided them through the process of structuring new franchises, raising capital and navigating through the legal and compliance documentation required by all franchise owners and future franchisees.
“Partnering with SoFran allows us to leverage their industry experience and successful track record in building Carmela’s into a recognizable brand in the marketplace. Our success will be based on developing a business model for our future franchisors that offers long-term success and sustainability,” commented Mr. Ronald Heineman, President of Greenfield Farms Food, Inc.
Shareholders of the Company can expect to receive additional updates as to the status of these and other developments in the coming weeks.
About Greenfield Farms Food, Inc.
Greenfield is a publicly-traded, nominally capitalized company, operating through its wholly-owned subsidiary Carmela’s Pizzeria CO, Inc. Carmela’s Pizzeria restaurants include pizza buffets, alcohol service, delivery and carry-out, depending on the location. Greenfield has previously been a limited producer and marketer of “grassfed” beef that supplied a North Carolina based grocer.
About Carmela’s Pizzeria
Carmela’s Pizzeria presently has three Dayton, Ohio area locations offering authentic New York style pizza. Carmela’s offers a full service menu for Dine In, Carry out and Delivery as well as pizza buffets in select stores. Carmela’s has been noted in the Dayton Daily News as one of “The Best Pizzerias” in Dayton. Visit the Carmela’s website at: http://www.carmelasohio.com
Safe Harbor for Forward-looking Statements
This news release may contain forward-looking statements that are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, they are based on management’s current beliefs and assumptions as to future events. However, since the company’s operations and business prospects are always subject to risk and uncertainties, the forward-looking events and circumstances discussed in this news release might not occur, and actual results could differ materially from those described, anticipated or implied. For a more complete discussion of such risks and uncertainties, please refer to the company’s filings with the Securities and Exchange Commission.
Contact Information:
Greenfield Farms Food, Inc.
Henry Fong
CFO
(561) 514-9042
(SKVI) Appoints Network Marketing Expert Dean Aldridge as Master Distributor
Kintari Launching Patented Skin Care Product Line
LAS VEGAS, NV–(Oct 29, 2014) – Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) — through its wholly owned subsidiary Kintari International Inc., makers of patented “Youth Renewed” skin care products — is pleased to announce the selection of R. Dean Aldridge in the key role of Master Distributor. Dean will spearhead distributor expansion and development globally.
“We are very pleased to have Dean Aldridge, a world class marketer and sales leader, as our Master Distributor for Kintari,” said Terry Howlett, President of Kintari. “The Master Distributor plays a crucial role in the upward trajectory of the number of distributors that join Kintari and the sales they produce. Dean has exactly the skills and experience to make Kintari a huge success.” He added, “Dean has proven his skills over the past fifteen years in the network marketing industry. He is a multiple award winner and has climbed to the highest level of every company he has been associated with. Dean is often referred to as one of the top recruiters as well as one of the best relationship builders our industry has seen. His expertise has taken him to the top echelons of financial rewards and is touted as one of network marketing’s most distinguished international leaders.”
“When I was introduced to Kintari’s patented technology and then met the corporate leadership team, I knew that this was a special opportunity that I had to get involved with,” said Dean Aldridge. “I was so impressed by the previous network marketing experience of Terry Howlett and Rob Barnes, Kintari’s Director of Sales whose previous network marketing company topped over $20 million per year in sales. This team not only has the industry experience but the understanding of what it takes to succeed, both for Kintari and its distributors. It’s a win-win. I was also impressed by the product line made with the patented Invisicare technology, which has the capability to change the network marketing industry forever. I knew that I had discovered the perfect opportunity; the right products, the right ownership and the right compensation plan — I was in.”
The Kintari product portfolio consists of “Youth Renewed” (YR) anti-aging products to help fight the signs of aging. These products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients are powered by our patented Invisicare® technology, providing consumers with unique, effective skincare benefits which cannot be duplicated.
Kintari has an exclusive license to patented Invisicare products from its parent company Skinvisible Pharmaceuticals, Inc., a science-based research and development company. Skinvisible continues to build its worldwide patent portfolio while seeking licensees for its prescription and over-the-counter dermatology products.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. In addition, Skinvisible’s wholly-owned subsidiary Kintari will commercialize cosmeceutical and OTC products globally through a direct sales channel. www.skinvisible.com www.invisicare.com www.kintari.com
Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10k for the quarter ending June 30, 2014).
Contact:
John Pentony
Investor Relations
Ph: 972-292-8930
Email: jpentony@skinvisible.com
(AMPG) Hiring of JP Fortune Group to Expand Operations, Shareholder Awareness
BOHEMIA, N.Y., Oct. 28, 2014 — AmpliTech Group, Inc. (OTCQB:AMPG) (“AmpliTech” or the “Company”), a trusted provider of RF/microwave, and low noise amplifiers for critical and high-reliability, wireless and commercial applications, is pleased to announce it has engaged JP Fortune Group. JPF is one of North America’s premier small-cap advisory firms. JP Fortune Group will assist the Company in capital structuring, debt management, M&A opportunities, development of a strategic advisory board, market positioning and shareholder communications. JPF will implement a comprehensive financial growth strategy and execute an extensive investor relations campaign. The company’s goal is to increase and exploit opportunity in the marketplace while maintaining a fair market value for its shareholders equity based on its unique technology and expertise.
“We are thrilled to partner with JPF to strengthen our financial operations while informing the investment community about our exciting company and its potential. It is just another step in the right direction with many more to follow,” said Fawad Maqbool, President & CEO of AmpliTech. “We are highly confident our combined efforts will garner successful results in a timely manner,” stated Larry Fortune of JP Fortune Group.
“We believe AmpliTech has developed a premier technology, and we are anxious to communicate the AMPG story to the investment community,” said James Moldenhauer, CEO of JPF.
Interested investors may contact James Moldenhauer at JPF at 714-420-2004.
About AmpliTech Group, Inc.
AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz – eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers’ own designs. Website: http://www.amplitechinc.com
About JP Fortune Group
JP Fortune Group; a Bryce Holdings, LLC brand is a premier independent investor relations and financial advisory firm, with the depth of experience and expertise to advise companies across a broad spectrum of industries, ranging in revenues from $5 million to over $500 million. With a combined management team experience exceeding 50 years, JP Fortune Group is a leader in providing the highest quality investor relations and financial consulting services for middle market companies across a wide spectrum of industries.
CONTACT: Fawad Maqbool
CEO
AmpliTech Group, Inc.
631-521-7831
Larry Fortune
Managing Partner
JP Fortune Group
949-344-0539
(CPPXF) Posts 2014 Annual Results
VANCOUVER, British Columbia, Oct. 28, 2014 — Continental Energy Corporation (OTCQB: CPPXF) (the “Company“) an emerging international energy investment company with operations in Southeast Asia and Tanzania, Africa, today announced the filing on SEDAR of its audited consolidated financial statements for the year ended 30 June 2014. Complete copies of these financial statements are available for download from the SEDAR website at www.sedar.com.
The Company incurred a net loss of $939,489 during the 2014 fiscal year compared to a net loss of $700,115 during the prior year, an increase of $239,374. The increase in loss was primarily due to the operations of the Company’s Norwegian subsidiary, Visionaire Energy AS (“VEN“) and its two affiliated companies. The Company uses the equity method to account for its portion of the operations of these affiliates and recorded a loss of $311,972 during the 2014 fiscal year while in the prior year; the Company recorded an income of $37,143. The Company had a loss per share of $0.01 in both 2014 and 2013 fiscal years.
As announced on 16 September 2014, the Company agreed to sell its 51% interest in VEN for total consideration of US$1,200,000 to Visionaire Invest AS that owns the other 49% of VEN. The effective date of the sale is set in the agreement at 30 June 2014. The operations of VEN and its affiliates are therefore classified as discontinued operations held for sale. The Company’s investment in its Norwegian subsidiary was reflected at $862,375 on 30 June 2013 and the carrying value of the investment decreased to $559,068 by 30 June 2014. The sale of VEN is subject to the approval from the shareholders of the Company at the Company’s annual general meeting scheduled for 5 December 2014.
As at 30 June 2014, the Company’s consolidated financial statements reflect a working capital deficit of $693,794. This represents a decrease in the working capital deficit of $50,898 compared to the 30 June 2013 working capital deficit of $744,692. Cash used in operating activities during the 2014 fiscal year totaled $533,013 compared to $189,464 in the prior year. The Company was able to generate more funds in the 2014 fiscal year and make the relevant payments towards its administrative costs. Cash from investing activities during the 2014 fiscal year was $1,219 whereas there was $15,544 expended on such activities during the prior year. Financing activities provided $42,948 in the 2013 fiscal year compared to $761,517 during the 2014 fiscal year primarily from a $750,000 loan that was converted to equity subsequent to 30 June 2014.
The Company also filed on SEDAR its annual reserves report for 2014 in the form referred to in Canadian National Instrument 51-101 “Standards of Disclosure for Oil and Gas Activities”. Complete copies of the reserves report are available for download from the SEDAR website, www.sedar.com.
On behalf of the Company,
Robert V. Rudman, C.A.
Chief Financial Officer
Further Info: www.continentalenergy.com
No securities regulatory authority has either approved or disapproved the contents of this news release.
Forward Looking Statements – Any statements in this news release that are not historical or factual at the date of this release are forward looking statements. There are many factors which may cause actual performance and results to be substantially different from any plans or objectives described in any forward looking statements. Readers should also refer to the risk disclosures outlined in the Company’s regulatory disclosure documents filed with the Securities and Exchange Commission available at www.sec.gov. The Company assumes no obligation to update the information in this release.
(GNOLF) Division Signs Contract With Genoil to Build a $700M Refinery
NEW YORK, NEW YORK–(Oct 28, 2014) – Genoil Inc. (OTCBB:GNOLF). Hebei Zhongjie Petrochemical Company Ltd., which operates as a subsidiary of CNOOC, signed a contract for a one million two hundred thousand tons per year refinery, utilizing the Genoil Upgrading Process. The Refinery will produce finished products for sale in the local Chinese market.
The previous engineering work and feasibility study done by the Chinese Petroleum Engineering Co, Ltd – Dalian Company, which is a division of Chinese National Petroleum Company (CNPC), will be the base for this new project. Genoil has already invested a substantial amount in the millions of dollars for this engineering work.
Hebei Zhongjie Petrochemical Company will make a 30% direct investment in the project. The profits are to be shared on a 50%-50% basis between Genoil and Hebei Zhongjie Petrochemical Company for the life of the project.
It has been the intention of CNOOC to significantly expand the annual refining capacity of Hebei Zhongjie Petrochemical Company’s refining operation. “Genoil is excited to be participating in their expansion plans” says David Lifschultz, CEO of Genoil.
Genoil Inc.
David K. Lifschultz
CEO
212 688 8868
(NSAV) Link Announces a Significant Addition to its Board of Directors
PORT JEFFERSON, NY, United States, via ETELIGIS INC., 10/28/2014 – – Net Savings Link, Inc. (OTC: Pink: NSAV) (PINKSHEETS: NSAV), today has announced a significant addition to its Executive Management Team and Board of Directors that will have a major impact on the continuing intermediate and long-term Corporate objectives that are being targeted by NSAV and Global Distribution Corp.
Steven Baritz, the CEO of NSAV said, NSAV is both pleased and proud to announce the appointment of Mr. Leonard Genovese as the President and Chairman of the Board of Net Savings Link, Inc. Mr. Genovese was a major figure in the family that built and operated the National chain of Genovese Drug Stores, Inc., one of the largest and most developed retail establishments in the United States. Mr. Genovese was the Vice President of Operations and Vice President of Marketing for the firm, which was sold to J.C. Penneys for $492 Million. During his tenure, the chain grew to 141 stores in NY, NJ, and CT, with over 5,000 employees, and when it was acquired by JC Penney, it had sales of over $800 Million at the time of acquisition. The stores were rebranded as Eckerd Drug Stores, and Rite Aid Drug Stores in NY, and are still operating and thriving today. Mr. Baritz continued; Mr. Genoveses decades of experience and contacts in the retail distribution sector are immense, especially within the wellness and food arenas, and are expected to create immeasurable opportunities and access for Net Savings Link and their subsidiaries, including our Nutra Horizon wellness product line along with other products that we are currently developing to bring to market. We are indeed fortunate to have him in a leadership capacity on our management team and Board of Directors. In fact, he is already engaged in discussions to generate revenues from both new product lines and access to distribution channels. Mr. Baritz continued; Included within his agreement with NSAV, Mr. Genovese has agreed to defer any salary until certain revenue metrics are attained, so that the company can minimize intermediate term expenses and concentrate on growth, access to distribution venues, and product development.
Mr. Baritz also provided an update on the Nutra Horizon wellness product line and its website. I am pleased to announce that our Nutra Horizon wellness product line has finished production and packaging, and is now available for release to the market. Mr. Baritz continued, It features NINE separate wellness products developed by our previously announced Oglethorpe Corp agreement, including a powerful Probiotic formulation that has a unique feature in that it can be taken in conjunction with some antibiotics , PRP Isolate Immune spray, 100% Colostrum formulation, Multiple flavors of concentrated vitamin and mineral compounds that have achieved observable results in the treatment of many illnesses, and received numerous user testimonials of the benefits. Mr. Baritz also commented on the Nutra Horizon website; Our Nutrahorizon website (www.Nutrahorizon.net) is officially open and features preliminary descriptions of the product line. The e-commerce portion of the site is still in its final development stage, and I expect the site to be fully complete and functional in terms of content, usability, and consumer access to purchase products within the next 30-45 business days. Mr. Baritz continued; We have already received strong positive feedback, along with many constructive suggestions from consumers and shareholders, and we are implementing those suggestions, including illustrations, detailed product information, and design changes into our refinements during the next 30-45 days of site development. At that time, consumers will be able to make purchases of the products directly from the website, which is expected to generate direct revenue to the company.
About Net Savings Link, Inc.
Net Savings Link, Inc. owns and operates a wholly owned subsidiary, Global Distribution Corporation, a distribution company that markets and distributes products in varying industries including the supplement, wellness and natural remedies markets. People interested in learning more about Global Distribution should check back with the company at its website, www.Globaldistributioncorp.net .
DISCLAIMER:
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information contained in this Press Release including such forward-looking statements.
CONTACT:
David Pecoraro,
Shareholder Relations Director
Email: DavidPecoraro@rocketmail.com
Tel : 814-418-6648
(ELRA) Wagering Exceeds $10M for the Month of October
NEW YORK, Oct. 28, 2014 — Elray Resources Inc. (OTCPK:ELRA) trading as Elray Gaming announced today that wagering in one of its JV Licensed Live Dealer Casino Facilities in Manila has already surpassed 10 Million USD for the month of October.
Brian Goodman, CEO stated that, “This is very encouraging as Elray has recently overcome some technical challenges in delivering the product into Asia and the encouraging and incremental wagering is as a result of the system now being stable and highly competitive in the world’s largest gaming arena – Asia. The expected yield of the live studio is around 2.5% of wagering and the facilities are highly scalable. Elray will shortly roll out additional Asian facing gaming products including a new fully integrated E-store and exclusive VIP club specifically targeting the Chinese market and in addition to gaming will also offer high ticket branded fashion and electronic items.”
About Elray
Elray is an established Gaming entity which owns and licenses Gaming Intellectual Property, Gaming Domains, Trademarks and Player Databases. Whilst Elray is a US company, we have a global presence with offices in London, South Africa, Sydney and Curacao, homes of the largest gaming operators, which helps us actively manage and serve our clients. Our sophisticated patented software automatically declines any gaming requests from within the United States, in strict compliance with current US law. Our Sydney office allows us to tap into skilled resources and some of the world’s largest client base, for regular, personal interaction. As our active operations are in a jurisdiction that is friendly to online gaming, our clients can rest assured that we are here to stay. www.elraygaming.com
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
CONTACT: Elray Gaming
Email: info@elraygaming.com
(NNAN) Establishes ViralProtec Division to Supply Personal Protective Ebola Equipment
ViralProtec Announces Purchase Order With California Hospital
ROCHESTER, NY–(Oct 28, 2014) – NaturalNano, Inc. (PINKSHEETS: NNAN) (www.naturalnano.com) announced today the formation of its ViralProtec Division (www.viralprotec.com) to service the growing demand for Personal Protective Equipment (PPE). The recent public concern and publicity surrounding the increased risk to caregivers and other responders created by the Ebola virus as well as other public health concerns has raised awareness of the need for additional precautionary steps for those dealing with these issues.
ViralProtec sells a range of personal protection equipment (PPE) including complete PPE suits which comprise of chemical protective suits, aprons, boots, gloves and a 3M Versaflo Powered Air Purifying Respirator Systems (PAPR). The Company has received a number of inquiries and orders.
Jim Wemett, CEO of NaturalNano, stated, “The Center for Disease and Control and Prevention has revised Ebola Gear Guidelines stating the need to be covered from head to toe with full protective clothing. In entering this strategic business line we recognized that it is very difficult to source a complete PPE solution from a single source. Our goal in launching ViralProtec is to fill that void in the market, and to date the response from the market place and potential customers has been remarkable.” Wemett continued, “By carrying a full line of protective gear and isolation chambers we will provide a valuable offering that can assist in making our health workers’ environment as safe as possible.”
About ViralProtec
ViralProtec (www.viralprotec.com) a wholly owned subsidiary of NaturalNano, is a reseller for best practices Ebola personal protective equipment (PPE) and ancillary supplies. Our mission is to provide personal protective equipment for patient care of those at risk during infectious disease patient care that meet or exceed CDC and WHO guidelines.
NaturalNano, Inc. (PINKSHEETS: NNAN) located in Rochester, New York, is engaged in the development and commercialization of material additives based on proprietary nanomaterial technology utilizing Halloysite Nanotubes (HNTs). For more information please visit www.naturalnano.com.
Cautionary Statement Regarding Forward-Looking Statements: Contains forward-looking statements regarding future events and future performance that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano’s filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-K and quarterly reports on Form 10-Q filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports filed with the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.
Contact:
Jim Wemett
NaturalNano, Inc.
585-267-4848
info@naturalnano.com
(NHMD) Announces It Has Agreed to Its Initial Contract to Sell Up To 100k Cans
Nate’s Food Co. Announces It Has Agreed to Its Initial Contract to Sell Up To 100,000 Cans
Los Angeles, California (FSCwire) – Nate’s Food Co. (OTC: NHMD) announced today that it has entered into an agreement to sell up to 100,000 cans. The Company is currently finalizing the pricing and delivery date.
The agreement is with an on-line store and represents our initial contract. Recently there has been an increase in on-line grocery delivery with companies such as Yummy.com, Amazon Fresh, Peapod.com and MaxDelivery. These stores represent multi-channel delivery ability that did not exist for Batter Blaster and could significantly increase the Company’s number of distribution points.
The Company is continuing to have talks with grocery stores and big box stores regarding placing Nate’s Pancakes in the same stores that Batter Blaster was sold.
The Company will provide additional information once the contract has been finalized.
About Nate’s Food Co.
Nate’s Homemade pancake and waffle batter are a ready-to-use, pre-mixed pancake and waffle batter delivered in a pressurized can. Our pre-made batter makes light and airy pancakes or waffles that are fun for the entire family to make together, and are a great way to start your day. With no preparation and no clean-up, we’ve made making breakfast easier for your busy mornings.
Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual and interim reports.
Contacts:
Nate’s Food Co.
Nate Steck
(661) 418-7842
info@nhmd.net
(ALXA) and Ferrer Expand ADASUVE® Partnership
Ferrer Purchases $8 Million of Alexza Common Stock through New Investment and Elimination of Potential Milestone Payments
MOUNTAIN VIEW, Calif. and BARCELONA, Spain, Oct. 27, 2014 — Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that they have amended their agreement for ADASUVE® (Staccato® loxapine). Ferrer is Alexza’s commercial partner for ADASUVE in the European Union, Latin America and the Commonwealth of Independent States countries (the Ferrer Territory). Ferrer and Alexza have agreed that Ferrer will purchase 2 million shares of Alexza common stock for $4.00 per share, thereby becoming the Company’s largest shareholder. The purchase represents a combination of new investment and consideration for the elimination of certain future potential milestone payments under the agreement.
“Ferrer and Alexza’s collaboration has been focused on building the market for ADASUVE in our territory and a lasting relationship between the companies,” said Jordi Ramentol, Chief Executive Officer of Ferrer. “The expansion of our relationship with Alexza with this strategic investment demonstrates our belief in ADASUVE as a highly valuable therapy, something we also hear from physicians and patients who have had experience with this product. We are pleased to continue our work together to build ADASUVE into a global brand.”
“We have been very pleased with Ferrer’s commitment and progress in bringing ADASUVE to patients since the first country launch in Germany in the summer of 2013. In addition to ADASUVE now being available in nine EU countries, Ferrer has secured three ADASUVE approvals in Latin America,” said Thomas B. King, Alexza’s President and CEO. “We continue to see momentum in the uptake of ADASUVE and consistently hear from physicians about the clinical benefits that ADASUVE can convey to the patients they treat.”
King concluded, “We are excited Ferrer is making this strategic investment in Alexza, which reinforces Ferrer’s commitment to ADASUVE as an important new therapeutic and to the long-standing collaboration between our two companies.”
About ADASUVE (Staccato loxapine)
ADASUVE is the first and only inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The EU marketing authorization for ADASUVE requires that patients receive regular treatment immediately after administration of the product to control acute agitation symptoms. It also requires that ADASUVE be administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side effects, such as bronchospasm.
Alexza and Ferrer estimate that as many as 8 million adults in the EU suffer from schizophrenia or bipolar disorder1. Agitation is a common symptom for these patients2, characterized by feelings of distress, anxiety and loss of control.
ADASUVE combines Alexza’s proprietary Staccato system with loxapine, an antipsychotic medicinal product. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in intravenous-like pharmacokinetics and rapid systemic effects.
The authorization for ADASUVE in the EU differs from that in the United States, with respect to the indication statement, dose regimen, available dose strengths, and risk mitigation and management plans. For more information about ADASUVE, including the Summary of Product Characteristics and Patient Information Leaflet approved in the EU, please visit the EMA website. For the full prescribing information including boxed warnings for the U.S., please visit www.adasuve.com.
About Ferrer
Founded in 1959, Ferrer is a privately-held European R&D-based pharmaceutical company headquartered in Barcelona. It is active in the pharmaceutical, health, fine chemicals and food sectors in Europe, Latin America, Africa, the Middle East, Asia and the United States. In total, Ferrer’s human healthcare products are commercialized in more than 90 countries, through 27 international affiliates (including joint ventures) and 70 partners and distributors.
Ferrer carries out activities throughout the full pharmaceutical value chain, from R&D to international marketing, including fine chemical development and the manufacturing of both raw materials and finished pharmaceuticals. Its research centers in Spain and Germany, and manufacturing sites in Europe and Latin America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and feed sectors. For more information, visit www.ferrer.com.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza’s products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.
ADASUVE is Alexza’s first commercial product, is based on the Staccato technology, and has been approved for sale by the U.S. Food and Drug Administration, the European Commission, and in Chile, Costa Rica and Guatemala.
Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza’s commercial partner for ADASUVE in the U.S. Ferrer is Alexza’s commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries. For more information, visit www.alexza.com.
ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
This news release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company’s expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and its partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company’s capital to support the Company’s operations, and the Company’s ability to raise additional funds and the potential terms of such potential financings. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and the Company’s other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
References:
1. Wittchen H.U., et al., 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 655-679.
2. Alexza data on file (primary market research among caregivers of patients with schizophrenia (95% have agitation) and bipolar patients (87% have agitation).
(PTRA) Hires Thompson Solutions, Technical Analysis At Sevier/Beaver Oil Project
Firm to Provide Initial Gravity and Magnetic Analysis at Sevier Oil Prospect
COLORADO SPRINGS, Colo., Oct. 27, 2014 — PetroTerra Corp. (OTCQB: PTRA) (“PetroTerra” or “the Company”), an independent oil and gas exploration company currently focused on the Sevier and Beaver Oil Project in west central Utah, announced today that it has engaged Thompson Solutions LLC (“Thompson”) to perform the next step in the technical analysis on the Company’s Sevier Oil Prospect.
“PetroTerra is excited to begin the development of its Sevier and Beaver Oil Project,” said John Barton, CEO of PetroTerra Corp. “By conducting an analysis of the gravity and magnetic data that already exists, and integrating the digital files and maps we receive from Thompson, this will aid us in identifying the most prospective trends and leads on our acreage and enable us to move to the second phase of development.”
PetroTerra Corp owns a 100% working interest and 80% net revenue interest in the Sevier and Beaver Oil Project, which is situated along the central Utah Thrust Belt. The Thrust Belt is a geologic feature that is part of an oil producing structural trend extending from Canada to the southern United States. The Company’s initial analysis will focus on the two Sevier County leases that comprise the Sevier Prospect.
Phase One Overview
Thompson will process both the public domain gravity and aeromagnetic datasets that currently exist over the Sevier Prospect. The public domain gravity data coverage is expected to be sufficient to identify major structures and geologic trends of interest. Integration of the gravity data with existing or to-be-acquired seismic will help to reduce interpretation ambiguities and to better characterize any potential risks as the project moves forward. The public domain aeromagnetic data will help delineate basement geologic structure and faulting that can impact migration and trapping of hydrocarbons in the overlying sedimentary section.
When processing of the public domain gravity and aeromagnetic data is complete, Thompson will provide PetroTerra with digitally enhanced files and maps. Analysis of these products will help PetroTerra focus on prospective trends and leads in the area. Based on the results of this analysis, a new detailed land gravity survey, and possibly a new high resolution aeromagnetic survey, will be considered for Phase Two.
About PetroTerra Corp.
PetroTerra Corp. (OTCQB: PTRA) is an independent oil and gas exploration company based in Colorado Springs, Colorado. The Company is engaged in identifying, evaluating and developing early stage onshore oil and gas opportunities in the domestic US. The Company’s strategy is to focus on a step-by-step approach to assets that are located in high potential, proven basins and to prudently develop and manage those assets to create maximum value for shareholders. The Company’s current focus is on the Sevier and Beaver Oil Project in west central Utah. The Company owns a 100% working interest and 80% net revenue interest in the project.
To learn more about PetroTerra Corp. please visit http://www.petroterracorp.com/.
About Thompson Solutions LLC
Thompson Solutions LLC provides integrated geophysical and geological interpretation solutions for the exploration of oil, gas, and minerals. They provide custom solutions that are based on integration of the client’s data with Thompson’s expertise in the interpretation of gravity, magnetic, and geological data.
Thompson Solutions was founded by Gary Thompson, a senior geophysicist and geologist with over 30 years worldwide experience with potential field geophysics, exploration geology, and Geographic Information Systems (GIS). His industry training and experience includes time with Unocal Corporation and the Superior Oil Company.
Cautionary Statement Regarding Forward Looking Information
This press release includes “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These statements include statements about our plans, strategies, financial performance, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by PetroTerra and its management team, are inherently uncertain. A more complete description of these risks and uncertainties can be found in our filings with the U.S. Securities and Exchange Commission. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
PetroTerra Corp.
422 East Vermijo Avenue
Suite 313
Colorado Springs, Colo. 80903
Tel: 719-219-6404
Fax: 719-219-6200
Investor Relations Contact
KCSA Strategic Communications
880 Third Avenue
New York, NY 10022
Brad Nelson / Jeffrey Goldberger
Toll Free: 1-800-787-2062
Email: ir@petroterracorp.com
(HPTG) Installation of HydroPlant on MPK Public Transportation Buses in Poland
Water-Based Hydrogen Fuel Production Systems Designed to Improve Fuel Efficiency and Reduce Greenhouse Gas Emissions
ATLANTA, GA and WROCLAW, POLAND–(October 27, 2014) – HydroPhi Technologies Europe S.A. (“HTE“), exclusive European licensee and distributor for HydroPhi Technologies Group, Inc. (OTCQB: HPTG), a developer of water-based, clean energy technology that delivers improved fuel economy and reduced greenhouse gas emissions, today announced the installation of its Hydroplant™ units on vehicles in Poland. Under the agreement executed with Miejskie Przedsiębiorstwo Komunikacyjne Sp z o.o. we Wrocławiu (“MPK Wroclaw”, “Municipal Transport Company in Wroclaw”), a large public fleet operator in the second largest city in Poland, the technology is being tested initially on two buses from October 15, 2014 and will continue to February 15, 2015.
HydroPlant™ technology uses an on-board, on-demand electrolysis system to separate hydrogen and oxygen from water, which is then injected into the air intake of engines utilizing carbon-based fuels such as diesel, unleaded gasoline and natural gas. HydroPlant™ is designed to eliminate the need for high-pressure hydrogen storage or hazardous chemicals while producing a stable, inexpensive alternative fuel source.
On October 15, 2014, two technicians from HPTG who traveled from Atlanta to Wroclaw conducted the installation and started the test phase of two Hydroplant™ units on two public transportation buses. The trials include a single bus and dual-articulated bus.
Roger Slotkin, CEO of HPTG, supervised the setup process and preparations for test phase. He participated in the meetings with management of MPK Wroclaw and representatives of HTE, to discuss the future cooperation and the opportunities offered by Hydroplant™ technology.
Patryk Wild, Vice President of MPK Wroclaw, stated, “MPK Wroclaw is looking for cost effective solutions to reduce fuel consumption and meet new environmental regulations. We believe HydroPlant offers a high return-on-investment and may be an ideal solution to fulfill the goals for our fleet, which includes over 340 buses that travel over 23 million kilometers per year.”
Wojciech Grzegorczyk, President of HydroPhi Technologies Europe S.A., commented, “We look forward to our cooperation with HydroPhi Technologies Group, Inc. and MPK Wroclaw, whereby these tests will serve as an important step forward and validation of the HydroPlant technology in Poland and Europe.”
Roger Slotkin, CEO of HPTG, commented: “We are excited to participate in these ground breaking trials of our technology in Poland. We also look forward to working with MPK and other potential customers in Europe to operate their fleets more cost effectively. Our plan is to continue our expansion across Poland and Europe in the upcoming months and years, where there is very high demand for fuel and emission reduction technologies. We have already received CE approval to market our products in Europe. We estimate the immediately addressable market for our technology in Poland, just on the current class of vehicles, to be over 250 million USD, and believe we can effectively penetrate most of this market within 5 years.”
About HydroPhi
HydroPhi Technologies Group, Inc. (“HPTG”), listed on OTC Market, is a developer of water-based hydrogen fuel production systems. The Company’s technology isn’t a fuel cell, nor is it a hydrogen alternative to traditional hydrocarbon fuels. The system utilizes distilled water for the production of hydrogen and oxygen, which is then injected into the air intake of an engine utilizing carbon-based fuels such as diesel, unleaded gasoline and natural gas. HPTG’s technology, (HydroPlant™) has been tested on transit buses in Mexico with reduced vehicle operating costs by improved fuel efficiency up to 20%, while lowering greenhouse gas emissions up to 70%. By using an on-board, on-demand electrolysis system, the technology eliminates the need for high-pressure hydrogen storage or hazardous chemicals while producing a stable, inexpensive alternative fuel source. By offering a real-time monitoring system as part of a hydrogen fuel solution with retrofit capability into standard vehicle engines, HPTG provides fuel efficiency to a potentially broad spectrum of users, including logistics, trucking, heavy equipment, marine and agriculture. Additional information about the Company and the technology is available at: www.hydrophi.com.
About MPK Wroclaw
Miejskie Przedsiębiorstwo Komunikacyjne Sp z o.o. we Wrocławiu (Municipal Transport Company in Wroclaw) is a public transport operator in the second biggest city in Poland – Wroclaw, dedicated to the carriage of passengers by both bus and tram vehicles. MPK Wroclaw fleet consist of over 340 buses and 432 tram wagons that are transporting annually more than 165 million passengers and are travelling over 34 million kilometers per year. Company has more than 2000 employees. More information at: www.mpk.wroc.pl.
Contacts:
David K. Waldman or Justyna Gudaszewska
Crescendo Communications Europe Sp. z o.o.
Tel : +1-212-671-1021
e-mail: hte@crescendo-ir.com
(RCPT) Positive P2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
– Study met primary efficacy and all secondary endpoints with statistical significance for patients on 1 mg dose after 8 weeks of treatment –
– Safety data are consistent with the favorable profile observed in Phase 2 trial in relapsing multiple sclerosis –
– Receptos plans to initiate Phase 3 program in ulcerative colitis and Phase 2 program in Crohn’s disease –
– Investor conference call and webcast today at 5:00 p.m. ET (2:00 p.m. PT) –
SAN DIEGO, Oct. 27, 2014 — Receptos, Inc. (Nasdaq:RCPT) today announced that TOUCHSTONE, the Phase 2 trial of RPC1063 in ulcerative colitis (UC), met its primary endpoint and all secondary endpoints with statistical significance in patients on the 1 mg dose of RPC1063 in the 8-week induction period. The overall safety and tolerability profile of RPC1063 was consistent with the results of the recent Phase 2 trial in relapsing multiple sclerosis (RMS), and continues to support the potential for orally administered RPC1063 to significantly improve the treatment paradigm for UC patients. The maintenance period of the TOUCHSTONE trial is currently ongoing.
This randomized, double-blind, placebo-controlled trial assessed the efficacy, safety and tolerability of two orally administered doses (0.5 mg and 1 mg) of RPC1063 in patients with UC across 57 sites in 13 countries. The trial enrolled 199 patients, approximately 10% higher than planned, due to a strong interest among investigators and patients to participate in the study. The primary endpoint of the trial, the proportion of patients in clinical remission at week 8 as defined by the industry standard Mayo scoring criteria, was achieved by 16.4% of patients on the 1 mg dose of RPC1063, as compared to 6.2% of patients on placebo, which was statistically significant (p<0.05). In the low dose group of 0.5 mg, 13.8% of patients achieved clinical remission, which was not statistically significantly different from the placebo group.
All secondary endpoints at week 8, including clinical response, change in the Mayo score and mucosal improvement on endoscopy were also positive and statistically significant for the 1 mg dose. Notably, 58.2% of patients on the 1 mg dose of RPC1063 achieved clinical response, as compared to 36.9% of patients on placebo (p<0.05). Trends were observed for all secondary efficacy endpoints for the 0.5 mg dose group that appear to demonstrate evidence of a dose response. The detailed results of the Phase 2 portion of the TOUCHSTONE trial are expected to be presented at a major scientific meeting in the coming months.
RPC1063 was generally well tolerated, and the incidence of adverse events across the active treatment groups and placebo appeared to be similar. Most adverse events were either mild or moderate in nature, and there appeared to be no concerning signals in the adverse events of special interest, including the cardiac and hepatic safety profiles. With regard to the cardiovascular profile, first dose mean changes in heart rate in patients receiving RPC1063 were generally modest during the first six hours after administration, which is consistent with the findings of the earlier Phase 2 trial in RMS and thorough QT study. Rates of liver transaminase elevations observed in patients receiving RPC1063 were low and consistent with the earlier Phase 2 trial in RMS.
“The results of this trial demonstrated a significant treatment effect of orally administered RPC1063 at the 1 mg dose, with what appears to be a clear dose response and consistency across both the primary and secondary efficacy endpoints,” said Dr. William Sandborn, M.D., Professor of Medicine and Chief, Division of Gastroenterology and Director, University of California San Diego Inflammatory Bowel Disease Center. “The results also showed a favorable overall safety profile. A Phase 3 program is clearly warranted in order to confirm and extend these results.”
Based on these results, Receptos plans to initiate a Phase 3 program in 2015 to compare the safety and efficacy of the 1 mg dose of RPC1063 to placebo in patients with UC. In addition, these results suggest the potential for RPC1063 to be used in the treatment of Crohn’s disease, a related inflammatory bowel disease. Receptos plans to initiate a Phase 2 study of RPC1063 for the treatment of Crohn’s disease in 2015.
“The positive results of the TOUCHSTONE study exceeded our expectations with respect to the treatment effect of RPC1063,” said Faheem Hasnain, President and Chief Executive Officer of Receptos. “The consistency of the efficacy data across the various endpoints for the high dose, combined with the favorable safety profile, gives us confidence to move forward expeditiously with Phase 3 trials in ulcerative colitis and a Phase 2 trial in Crohn’s disease. There is a tremendous unmet need for a novel orally administered therapy in these patient populations. In addition, we believe that RPC1063 may have promise in other therapeutic areas, and we intend to continue to explore other autoimmune indications where RPC1063 may provide utility.”
Conference Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time)
The Receptos management team will host a teleconference and webcast to discuss the information in this press release. The live call may be accessed by phone by calling (866) 757-6808 (domestic) or (760) 536-5211 (international), conference ID 26817792. The webcast can be accessed live on the Investor Relations section of the Receptos website at www.receptos.com and will be archived for 14 days following the call. A replay of the call will be available by phone by calling (855) 859-2056, participant code 26817792.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company’s lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Patents supporting RPC1063 were exclusively licensed to Receptos from The Scripps Research Institute (TSRI).
About TOUCHSTONE
TOUCHSTONE is a randomized, double-blind, placebo-controlled Phase 2 trial investigating the effect of two orally administered doses of RPC1063 versus placebo in patients with moderately to severely active ulcerative colitis. This trial enrolled 199 patients across 57 sites in North America, Europe and Asia Pacific. The trial consists of an 8-week induction period followed by a blinded 24-week maintenance period for patients achieving clinical response during the induction period. The maintenance portion of the trial is ongoing and is expected to be completed in 2015. Additional information regarding TOUCHSTONE is available at www.clinicaltrials.gov (NCT01647516).
Forward-Looking Statements
Statements contained in this release, other than statements of historical fact, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “expects,” “believes,” “may,” “intends,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as RPC1063 constitute forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation consistency of trial results to date with further trial results, the Company’s ability to adequately and timely recruit and enroll patients in its clinical trials, as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in the Company’s SEC filings, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and the Company’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2014 and June 30, 2014. All forward-looking statements contained in this release speak only as of the date on which they were first made by the Company, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after such date.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
(VTAE) Exercise of Underwriters’ Option to Purchase Additional IPO Shares
FORT WASHINGTON, Pa., Oct. 27, 2014 — Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, after underwriting discounts and commissions and estimated offering expenses, was approximately $56.0 million.
Stifel and BMO Capital Markets acted as joint book-running managers and JMP Securities and Wedbush PacGrow Life Sciences acted as co-managers for the IPO.
A copy of the final prospectus related to the IPO may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Telephone: (415) 364-2720, email: syndprospectus@stifel.com; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 27th Floor, New York, NY 10036, Telephone: (800) 414-3627, email: bmoprospectus@bmo.com.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 24, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
CONTACT: Investors:
Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
(215) 461-2000
rmorris@vitaerx.com
Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com
or
Media:
6 Degrees PR
Tony Plohoros
(908) 940-0135
tplohoros@6degreespr.com
(MNGG) Buys Back Debt to Avoid Dilution
WICKENBURG, AZ–(Oct 27, 2014) – Mining Global, Inc. (PINKSHEETS: MNGG) announced today that it has repurchased $100,000 of outstanding notes to prevent as many as one billion shares from hitting the market in December in an effort to avoid more dilution of its common stock.
“This is not an easy task that we are doing for our shareholders, but it will show the direction of the company’s goals,” said Joel J. Natario, Chief Executive Officer of Mining Global, Inc. “Our next step is to start buying back shares in November.”
Disclosures can be found on the Company’s online disclosure portal at: http://www.otcmarkets.com/stock/MMNG/filings
Please visit our new Investor Board we have teamed up with to educate our shareholders at: http://investorshangout.com/Mining-Global-Inc-MNGG-87629/
About Mining Global Inc.
Mining Global’s objective is to build and operate world-class mines and develop a robust portfolio of assets in North America with the focus on organic growth and early stage acquisitions. The exceptional experience and strength of Mining Global’s management team, combined with the excellent infrastructure and robust economics of the Arizona mining industry, sets Mining Global to become a leading Gold development and mining company.
Forward-looking statements:
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential,” or “continue,” or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.
Investor Relations
Mining Global, Inc.
660 Via Corte, Suite B
Wickenburg, AZ 85390
Website: http://miningglobalinc.com/
Phone: 928-232-0478
Email: Email Contact
(OMEX) HMS Victory (1744) Shipwreck Project Receives Approval From UK Ministry of Defence
Odyssey Marine Exploration to Conduct Operations as Exclusive Archaeological Contractor
TAMPA, Fla., Oct. 24, 2014 — Odyssey Marine Exploration, Inc. (Nasdaq:OMEX), a pioneer in the field of deep-ocean exploration, welcomes today’s statement by the United Kingdom’s Secretary of State for Defence giving consent to proceed with the archaeological investigation and recovery of at-risk artifacts from the HMS Victory (1744) wreck site in accordance with the project design that has been approved by the UK Ministry of Defence (MOD) and Department for Culture Media & Sport (DCMS).
In 2008, Odyssey discovered the shipwreck of HMS Victory (lost 1744) and with the permission of the MOD recovered two cannon to aid positive identification of the shipwreck. The MOD and the DCMS held a joint public consultation on options for the management of the site. In January 2012, a deed of gift transferred the Victory (1744) and associated materials belonging to the Crown to the Maritime Heritage Foundation (MHF), a UK charity. The MHF will next submit the necessary application to the UK Marine Management Organisation to allow operations to begin.
As the exclusive archaeological contractor to the MHF, Odyssey will undertake the activities as outlined in the approved project design, including recording, documentation, conservation and publication. All recovered artifacts will be declared to the Receiver of Wreck in accordance with UK legislation.
“We are looking forward to sharing the progress of this exciting archaeological project and the stories told by the recovered artifacts with the public,” said Lord Lingfield, chairman of the Maritime Heritage Foundation. “HMS Victory is the only wreck of a first-rate English warship discovered underwater anywhere in the world. Odyssey’s archaeological experience with this shipwreck, as well as with many other projects throughout the world, gives us great confidence this important project will be conducted to the highest standards.”
Odyssey president and CEO Mark Gordon commented, “This is an exemplary project for Odyssey that can demonstrate how cooperation between the public and private sectors can benefit business, the government and the public. We are committed to conducting this archaeological project with the greatest of care and concern as we utilize advanced technology, defining procedures, and experts for recording, documentation, recovery, conservation and publication.”
About HMS Victory
The predecessor to Nelson’s favorite warship, HMS Victory was launched in 1737 and later became the flagship of the Channel Fleet. She was lost less than a decade later during a violent storm in October 1744. The Victory is unique as the only scientifically-studied wreck of a first-rate English warship found in the world’s oceans.
Between February and August 2012, Odyssey conducted, on behalf of the Maritime Heritage Foundation, a comprehensive non-disturbance survey that completed the non-disturbance sections (phases 1-2) of the project design. The wide ranging initiatives applied included side-scan and multibeam sonar, production of two photomosaics, the recording of all surface features, remote geophysical sensing for ferrous (FADE), non-ferrous (TSS) and other sub-bottom imaging anomalies (SBI), and an environmental and marine biological site assessment contracted to the University of St. Andrews, Scotland. Three sacrificial frames containing metal and wood samples were buried offsite as part of an environmental studies program.
Five papers detailing this non-disturbance work have been published, including ‘HMS Victory (Site 25C). Preliminary Results of the Non-Disturbance Shipwreck Survey, 2012.‘ These scientific papers, as well as eight others related to Victory, are available at www.victory1744.org, a website dedicated to Victory that includes a unique virtual dive trail.
About the Maritime Heritage Foundation
The Maritime Heritage Foundation is a registered charity founded in April 2011 by its chairman, Lord Lingfield. The Foundation’s mission is to educate the public about maritime heritage. The Victory 1744 Project is intended to further that mission by conducting an archaeological excavation of the shipwreck, recovering, conserving and studying cultural heritage associated with the shipwreck, and sharing the information and recovered artifacts with the public through exhibits, publications, websites and educational programmes. The Maritime Heritage Foundation is advised by its Scientific Advisory Committee chaired by marine archaeologist, Dr. Margaret Rule. The Foundation has selected Odyssey Marine Exploration to serve as exclusive archaeological contractor for the project and Wreck Watch International to serve as archaeological consultant.
About Odyssey Marine Exploration
Odyssey Marine Exploration, Inc. (Nasdaq:OMEX) is engaged in deep-ocean exploration using innovative methods and state of-the-art technology. Odyssey has surveyed and mapped more than 26,000 square miles of seabed and spent more than 15,000 hours diving on shipwreck sites using advanced robotic technology. The company has discovered hundreds of shipwrecks ranging from fifth-century BC Punic sites to German U-boats and Colonial warships.
Odyssey has published 43 archaeological and scientific papers available online and in four volumes of hardbound Oceans Odyssey books. More than 2 million people have been educated and entertained by Odyssey’s traveling exhibit, which features more than 500 artifacts combined with shipwreck history. Odyssey’s finds are also available globally at OdysseysVirtualMuseum.com. Odyssey’s work has been featured in more than 16 hours of prime-time TV programming on the Discovery Channel, National Geographic programming on PBS, NBC, and MSNBC, as well as National Geographic magazine and other national publications.
For additional details about Odyssey, visit www.odysseymarine.com. You can also follow the company on Facebook (www.facebook.com/OdysseyMarine) and Twitter (@OdysseyMarine).
Important Cautions Regarding Forward Looking Information
Odyssey Marine Exploration believes the information set forth in this Press Release may include “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the Securities and Exchange Commission on March 17, 2014. The financial and operating projections, as well as estimates of mining assets, are based solely on the assumptions developed by Odyssey that it believes are reasonable based upon information available to Odyssey as of the date of this release. All projections and estimates are subject to material uncertainties, and should not be viewed as a prediction or an assurance of actual future performance. The validity and accuracy of Odyssey’s projections will depend upon unpredictable future events, many of which are beyond Odyssey’s control and, accordingly, no assurance can be given that Odyssey’s assumptions will prove true or that its projected results will be achieved.
CONTACT: MEDIA CONTACTS:
Liz Shows
Odyssey Marine Exploration, Inc.
(813) 876-1776 x 2335
lshows@odysseymarine.com
INVESTOR RELATIONS CONTACT:
Ron Both
Liolios Group, Inc.
(949) 574-3860
OMEX@liolios.com
(CANV) CEO Releases Letter to Stockholders/Customers Rebuffing Project CBD
LAS VEGAS, Oct. 24, 2014 — CannaVEST Corp. (OTC:CANV), a leading manufacturer and distributor of hemp and cannabidiol (CBD) based products, released a letter from Michael Mona, Jr., Chief Executive Officer, to stockholders and customers regarding a recent report issued by Project CBD:
Dear Stockholders and Customers,
First, thank you for your continued support of and belief in our company. As you may be aware, on October 14, 2014, Project CBD, an organization claiming to be an educational service on the medical utility of the cannabis plant, issued a “special report” titled Hemp Oil Hustlers. In the report, Project CBD makes numerous allegations against individuals and companies in the CBD industry who are not involved with or related to our company. However, of particular concern are the allegations and statements of purported fact concerning the quality and safety of our products.
We owe it to our stockholders and customers to respond to such allegations. The claims disparaging our products are based on scientific inconsistencies, critical flaws in the methodology used to perform tests and false data. Our industry as a whole is subject to numerous attacks, and typically we do not merit such attacks with a response. In this instance, where the quality and safety of our products is attacked, we owe it to our customers and stockholders to respond.
Our methods for processing our hemp oil are expertly controlled from seed to sale. We have invested substantial effort and capital in establishing a world-class research laboratory and processing facility to ensure that our processes for purifying and processing cannabidiol (CBD) exceed all applicable standards. Our lab has achieved purification in excess of 97% on natural (non-synthetic) hemp-based CBD, and our processes and the efforts of our scientific team should be applauded and not disparaged.
With regard to the specific allegations made by Project CBD:
- Residual Solvents and Heavy Metals – We do not use solvents in our extraction process. However, the Project CBD report claims that two of the five samples of RSHO tested positive for residual solvents. The Report states “these are all class one solvents, the most dangerous and toxic class of solvents.” First, the solvents identified by Project CBD in the report (hexane, pentane, butane and ethyl acetate) are, in fact, not Class I solvents as defined by the United States Pharmacopia (USP). The identified solvents are either Class II or Class III solvents, and the USP has set acceptable exposure limits for Class II and Class III compounds.With respect to heavy metals, our products have, without exception, tested below the practical quantitation limits for the industry standard ICP-MS method as set forth in Steep Hill’s monograph titled, “Testing Cannabis for Contaminants.” Quite simply our products fall safely in line with the applicable standards, and the Project CBD report is uninformed and just plain wrong.
- Testing Methods – In addition, the conclusions reported as fact by Project CBD are based on suspect methods. First, Project CBD concedes its sample batches had no chain of custody controls. The samples (allegedly) tested by Project CBD were obtained from third parties. Also, the laboratory used by Project CBD (Flora Research Laboratories) had critical flaws in its methodology – flaws that would prevent the release of data by any reputable, unbiased lab. Specifically, the analysis performed by Flora Research confirmed there were major residue impurities on their injection needle that would lead to carryover between samples. Flora Research also employed shoddy procedures relating to the wash out of nonpolar hemp oil from their needle, which would not dissolve the hemp oil matrix.Based on the testing methods utilized by Flora Research, and what is likely a bias based on its relationships with other CBD suppliers, Project CBD’s data should be disregarded. Although written in a manner to suggest it is objective journalism, the Report should be read for what it is – an effort to discredit our company for the benefit of its competitors.
We have asked the Director of Project CBD, Martin A. Lee, to work with us to vet his conclusions and statements in the interest of ensuring the public has accurate and reliable data concerning our products. Mr. Lee has accepted our invitation and we plan to educate Mr. Lee on our processing methods and protocols. We also will work with Project CBD to provide reliable and accurate test results. Ultimately, we are confident Project CBD will agree its report is fatally flawed as it relates to its conclusions about our products. We look forward to working with Project CBD, because we are confident our processes and end products are the highest quality in the world.
My intention with this letter is to ensure our stockholders and our customers have accurate data concerning the viability and safety of our products. We stand behind our processes and procedures, and we are proud of what we have accomplished to date. We continue to work hard to become world’s largest – and most respected – developer of CBD-based products.
Michael Mona, Jr.
CEO
CannaVEST Corp.
About CannaVEST Corp.
CannaVEST Corp. (OTCBB:CANV), based in Las Vegas, Nevada, focuses on the procurement and wholesale of the hemp plant extract cannabidiol (CBD), and the development, marketing and sale of end consumer products containing CBD, which is refined into its own PlusCBD Oil™ brand. CannaVEST resells raw industrial hemp product to third parties, acquired through supply relationships in Europe. Additional information is available from OTCMarkets.com or by visiting www.cannavest.com.
CannaVEST Corp.’s subsidiaries include CannaVest Laboratories, LLC (www.CannaVestLabs.com), which facilitates cutting edge research and develops nutraceutical and food products, containing cannabidiol (CBD) oil, and is the developer and manufacturer of CannaVEST’s own award winning CBD Simple™, and US Hemp Oil, LLC (www.USHempOil.com), which provides seed procurement, cultivation, processing, and production consultation, and equipment to support U.S. farmers, researchers and businesses to cultivate and process industrial hemp in the US.US Hemp Oil plans to build seed-processing mills and bring hemp-based products to market.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of CannaVest Corp. to be materially different from the statements made herein.
(SIMH) Caregiver TouchFree Infrared Clinical Thermometer Awarded
Annual Event Identifies Healthcare Products That Improve Patient Outcomes and Enhance Patient and Provider Safety
MIAMI, Oct. 24, 2014 — Thermomedics, Inc, a division of Sanomedics (OTCQB:SIMH) announced that its Caregiver® TouchFree™ Clinical Thermometer was awarded the coveted Innovative Technology designation by Novation at its Innovative Technology Expo on Sept. 10, 2014, at the Irving Convention Center, Irving, Texas.
The Caregiver does not require probe-covers, since it does not contact the patient, making it ideal for reducing risk of transmission of infectious disease. It takes temperature in 1-2 seconds and is easy-to-use with minimal inservice. The lack of probe covers also contributes to reduction of plastic waste and reduces costs for storage, as well.
The Caregiver was awarded the Innovative Technology designation following a review by more than 200 attendees from hospitals around the United States who serve on a Novation council or task force and participated in the Expo. These key opinion leaders indicated the Thermomedics Caregiver device offered incremental benefit over other products available on the market.
Olya Carter, RN and Senior Clinical Manager at Novation said, “Hospital participants strongly supported the Thermomedics Caregiver TouchFree Thermometer. They identified the Caregiver as the way to provide superior patient care by allowing them to efficiently assess their patients in the safest possible way.”
Keith Houlihan, Company President, noted that “this medical instrument is a breakthrough in patient care and reduces costs, time and technique-dependence while upgrading standards of practice. Our TouchFree technology is the world leader in contagion risk avoidance.”
This new designation will also identify Thermomedics’ Caregiver® TouchFree™ Clinical Thermometer as an awarded Innovative Technology product within Novation’s online contract catalog, which is accessible by the more than 100,000 members and affiliates of VHA Inc., UHC, Children’s Hospital Association, and Provista served by Novation. This heightened visibility will encourage further consideration by members accessing this agreement.
To learn more about Novation’s Innovative Technology program, visit www.novationco.com/expertise/technology.
About Sanomedics International Holdings, Inc.
Sanomedics International Holdings, Inc. (OTCQB:SIMH) is a medical technology holding company that focuses on game changing products, services and ideas — a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. Sanomedics plans to grow existing business organically and through strategic acquisitions specifically relating to healthcare technology and services.
Sign up for Sanomedics email news alert system today at: http://ir.stockpr.com/sanomedics/email-alerts.
Follow us on Twitter @Sanomedics and tweet us!
About Novation, Winner of the Ethics Inside® Certification
Founded in 1998, Novation is the leading health care supply chain expertise, analytics and contracting company for the more than 100,000 members and affiliates of VHA Inc. and UHC, two national health care alliances, Children’s Hospital Association, an alliance of the nation’s leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 800 suppliers. Members of VHA, UHC, Children’s Hospital Association and Provista used Novation contracts to purchase approximately $49 billion in 2013. Novation has earned the coveted Ethics Inside® Certification from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance. Novation was also named on Ethisphere’s World’s Most Ethical Companies list and is the only company in the health care industry to earn both distinctions for three consecutive years. To learn more about Novation, please visit http://www.novationco.com and follow @NovationNews.
Forward Looking Statements
This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties (for example, the risk that the acquisition is not consummated), and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The Company’s periodic filings with the Securities and Exchange Commission should be viewed for a complete understanding of risk and uncertainty.
CONTACT: Keith Houlihan
Sanomedics International Holdings, Inc.
info@Sanomedics.com
(VIZC) In-Depth Feature TV Interview On “New To The Street”
NEW YORK, NY–(Oct 24, 2014) – “New To The Street,” a television show that profiles public companies across national TV networks and social media channels with in-depth anchor driven reporting, will be airing the first of a six-part series on Monday, October 27, 2014 at 7:00 am on ION’s New York Flagship Station WPXN featuring DS Healthcare Group.
This interview features Daniel Khesin, CEO, talking about DS Healthcare Group’s (NASDAQ: DSKX) DS Laboratories high-end hair re-growth shampoo and related products, from their packaging to the highest source ingredients and how DS Laboratories puts their customers’ experience first. “New To The Street” will be visiting their headquarters in Miami Florida later this year and continuing the news series on this cutting edge company in following their progress, sales & development.
“Anyone who has used their products has seen and felt firsthand that the quality is stand alone and unlike any other in the industry. That is one of the reasons we have decided to become involved in sharing this company’s story with the masses,” said Vince Caruso, producer, “New To The Street.”
This show also featured VixConnect (OTCQB: VIZC) with Ed Carroll and Paul Cooleen speaking about their cutting edge social celebrity technology.
“New To The Street” will also be airing this show on Fox Business and possibly the Canadian Rogers Network, dates to be announced.
For further information: www.dslaboratories.com
“New To The Street” paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis and public company profiles. “New To The Street” is produced by FMW Media Works Corp. a leading provider of business profiles and corporate special programming, and airs as paid-programming on ION Media Networks, and airs in the United States reaching more than 95 million home. Visit www.newtothestreet.com.
New To The Street Contacts
Vincent Caruso
Office: 631-465-0284
Cell: 631-682-8499
Email Contact
(INNV) Receives Approval for the Expanded Label Indication for Zestra in Canada
SAN DIEGO, CA / October 24, 2014 / Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) www.innovuspharma.com (OTC: BB: INNV) today announced that it has received approval from Health Canada for an expanded label for its marketed Zestra(R) product. Zestra(R) is currently approved and marketed in Canada for the indication of “Temporary Increase of Desire in Female Sexual Desire Disorder Women (“FSDD”)”. The new indication approved is expanded to that of “Temporary Increase of Desire/Arousal in Women with Female Sexual Interest/Arousal Disorder” (“FSI/AD”).
FSI/AD, is a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. FSI/AD is a larger market that that of FSDD and published papers on the FSI/AD market size such as Harris, Interactive Women’s Sexual Health Survey (2009) estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger with an estimated over 20 million women suffering in the US and over 2 million women suffering in Canada.
There are no current prescription products approved in Canada or anywhere in the world for this indication which makes Zestra(R) a very valuable product to treat such an indication where it is approved.
Zestra(R) is the only OTC natural product clinically proven in two U.S. double-blind, placebo controlled trials in 276 women to increase arousal, desire and reduce pain during sexual intercourse. Zestra(R) is currently commercialized in the U.S. by the Company and in Canada by the Company’s licensing partner, Orimed Pharma Inc., a subsidiary of Jamp Pharma, and has sold millions of units since its launch in 2007. According to Laumann, E.O. et al. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999. vol. 281, No. 6.537-542 and deKadt Zestra Quantitative Consumer Study, October 2009, 43% of women have sexual difficulties as compared to ~31% of men who have erectile dysfunction (a market size close to $6B worldwide).
“The expanded label makes Zestra(R) the only product approved and marketed in Canada for FSI/AD and makes the product the first-to-market for this large therapeutic indication in this country”, said Dr. Damaj, President & Chief Executive Officer of the Company. “Our efforts to commercialize this product in additional markets such as Europe are moving forward as the Company is preparing for scientific guidance from the European Medicine Agency for filing Zestra(R) as a Herbal-based Medicine in Europe for the same indication,” continued Dr. Damaj.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra(R) for female arousal, and EjectDelay(TM) for premature ejaculation, and has a total of four marketed products in this space including Sensum+ (formerlyCIRCUMSerum(TM) (for sales outside the U.S. only) and Zestra(R) Glide.
For more information, go to www.innovuspharma.com.
INNOVUS PHARMA’S FORWARD-LOOKING Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra(R) in Canada, to successfully commercialize such products, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.
Innovus Pharma Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930
(LTNC) Elects New Board Member
HIRAM, GA / October 24, 2014 / Labor SMART, Inc. (LTNC) (the “Company”), a leader in providing on-demand blue collar staffing primarily in the southeastern United States, today announced that James Robert “Bobby” Edmonds of California, has been elected to the company’s board of directors. This brings the current total of directors to three.
Mr. Edmonds brings 17 years of experience in IT infrastructure and operations, including 14 years of software and application development expertise. He has held positions in networking, telecommunications, cloud and mobility solutions, both for B2B and B2C. In recent years his efforts have focused on tactical, strategic and marketing aspects of enterprise product development in his position of principal product manager at ServiceNow, a cloud services company.
“Bobby provides Labor SMART with a unique perspective and additional expertise to our board,” said Ryan Schadel, CEO of Labor SMART. “He is recognized as one of Silicon Valley’s experts in platform development and we believe that as we grow our business, seek new ways to engage with customers, and work to consolidate systems to bring about better EBITDA margins, his expertise will be of great value.”
“It is a great opportunity and an exciting time to join the board of directors of Labor SMART,” said Mr. Edmonds. “I look forward to supporting Mr. Schadel and his team as they continue to grow Labor SMART into the market disruption it was designed to become. The future of Labor SMART is a bright one and I am honored to be a part of it.”
Mr. Edmonds is 37 and is a U.S. Air Force veteran. He resides in Silicon Valley, California.
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Labor SMART, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may”, “would”, “will”, “expect”, “estimate”, “can”, “believe”, “potential”, and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Labor SMART, Inc.’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Labor SMART, Inc.’s filings with the U.S. Securities and Exchange Commission.
Contact:
Beverly Jedynak
Martin E. Janis & Company, Inc.
312-943-1123
bjedynak@janispr.com
(GTATQ) Announces Settlement Agreement With Apple
GT Retains Ownership of Production Assets in Mesa and Ability to Sell ASF(R) Furnaces in the Marketplace Without Restrictions
MERRIMACK, N.H., Oct. 23, 2014 — GT Advanced Technologies Inc. (OTC Pink:GTATQ) and Apple have reached a settlement agreement under which GT will wind down its sapphire materials production in the company’s Mesa, AZ and Salem, MA locations. The company indicated that it will exit from the market as a producer of sapphire materials and will refocus its business as an equipment supplier, manufacturing and developing sapphire growth systems and processes.
Under the terms of the settlement agreement, which is subject to approval by the Bankruptcy Court, GT will be released from all exclusivity obligations under its various agreements with Apple. GT will retain ownership of all production, ancillary and inventory assets located in Mesa and Apple is provided with a mechanism for recovering its $439 million pre-payment made to GT over a period of up to four years without interest, solely from a portion of the proceeds from ASF® sales. The agreement provides for a mutual release of any and all claims by both parties. As a result of the agreed upon terms, GT retains control of its intellectual property and will be able to sell its sapphire growth and fabrication technology, including ASF and Hyperion™, without restrictions.
GT and Apple will continue their technical exchange involving the development of processes for growing next generation sapphire boules as GT continues to build on its successfully deployed ASF115Kg technology and expand its range above 165Kg.
“We are pleased with the settlement that we have negotiated with Apple,” said Tom Gutierrez, president and chief executive officer. “We realize that our filing for Chapter 11 protection has caused uncertainty and hardship for many of our important stakeholders. We have been working diligently to develop a restructuring plan that will allow us to emerge from Chapter 11 as quickly as possible and with the operating flexibility and resources to position GT for long-term success. This agreement with Apple is an important step in that direction as it will allow us to monetize our advanced sapphire growth and fabrication technologies in an unrestricted manner. In addition to continuing to sell our industry leading sapphire equipment, we remain committed to advancing our Merlin™, Hyperion™ and next-generation PV and polysilicon solar solutions.”
As a result of the decision to wind down its sapphire materials operations, earlier this week GT initiated the process of shutting down the Mesa facility and approximately 650 Mesa employees have been laid off. A group of Mesa employees will remain on board to help with the wind down of the facility over the coming months. The company expects that there will be additional reductions-in-force implemented in the coming days, which will impact its Salem, MA, Merrimack, NH and select Asia locations.
“We recognize and regret the impact that these actions have on our valued employees and their families and we are committed to supporting them through this transition,” Gutierrez concluded.
A redacted version of the Settlement Agreement is attached to this press release: http://media.globenewswire.com/cache/25489/file/29707.pdf
GT will file its motion seeking bankruptcy court approval of the settlement agreement on Monday October 27, 2014, and the Bankruptcy Court is scheduled to hear such motion on November 25, 2014.
About GT Advanced Technologies Inc.
GT Advanced Technologies Inc. is a leading diversified technology company producing advanced materials and innovative crystal growth equipment for the global consumer electronics, power electronics, solar and LED industries. Its technical innovations accelerate the use of advanced materials, enabling a new generation of products across this diversified set of global markets. For additional information about GT Advanced Technologies, please visit www.gtat.com.
Forward-Looking Statements
Some of the information in this press release relates to future expectations, plans and prospects for the Company’s business and industry that constitute “forward-looking statements” for the purposes of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology. Forward-looking statements include, but are not limited to the following: the Company will wind down its sapphire materials production in the company’s Mesa, AZ and Salem, MA locations; the Company will exit from the market as a producer of sapphire materials and will refocus its business as an equipment supplier, manufacturing and developing sapphire growth systems and processes; the Company will retain control of its intellectual property and will be able to sell its sapphire growth and fabrication technology, including ASF and Hyperion™, without restrictions; the Company and Apple will continue their technical exchange involving the development of processes for growing next generation sapphire boules as the Company continues to build on its successfully deployed ASF115Kg technology and expand its range above 165Kg; the agreement with Apple will allow the Company to monetize its advanced sapphire growth and fabrication technologies in an unrestricted manner; and the Company expects that there will be additional reductions-in-force implemented in the coming days, which will impact its Salem, MA, Merrimack, NH and select Asia locations. These forward-looking statements are not a guarantee of performance and these statements involve certain risks and uncertainties that may be beyond the Company’s control and may cause actual future results to differ materially from our current expectations both in connection with the settlement agreement with Apple, the Chapter 11 filings and the Company’s business and financial prospects. Statements of management’s expectations, including its ability to successfully restructure, to address its financial challenges, obtain debtor-in-possession financing, the ability to address important issues in an orderly way and to make the Company stronger and more competitive are based on current assumptions and expectations. No assurance can be made that these events will come to fruition. Factors that could affect our results include, but are not limited to: (i) market demand for the Company’s equipment tools (including ASFs), (ii) the ability of the Company and its subsidiaries to continue as a going concern, (iii) the ability of the Company to obtain debtor-in-possession financing in adequate amounts; (iv) the ability of the Company and its subsidiaries to obtain Bankruptcy Court approval with respect to motions in the Chapter 11 cases, (v) the ability of the Company and its subsidiaries to prosecute, develop and consummate one or more plans of reorganization with respect to the Chapter 11 cases, and (vi) the effects of the bankruptcy filing on the Company and its subsidiaries and the interests of various creditors, equity holders and other constituents. Other factors that may cause actual events to differ materially from those expressed or implied by the forward-looking statements and various other risks are outlined in GT Advanced Technologies Inc.’s filings with the Securities and Exchange Commission, including the statements under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 28, 2014 and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Statements in this press release should be evaluated in light of these important factors. The statements in this press release represent GT Advanced Technologies Inc.’s expectations and beliefs as of the date of this press release. GT Advanced Technologies Inc. anticipates that subsequent events and developments may cause these expectations and beliefs to change. GT Advanced Technologies Inc. is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.
CONTACT: Media
GT Advanced Technologies Inc.
Jeff Nestel-Patt
Jeff.Nestelpatt@gtat.com
603-204-2883
Investors/Analysts
GT Advanced Technologies Inc.
Ryan Flaim
Ryan.Flaim@gtat.com
603-681-3689
(RCHA) Submission of IND for AML and Myelodysplastic Syndrome
BEVERLY HILLS, Calif., Oct. 23, 2014 — Rich Pharmaceuticals, Inc. (OTCQB:RCHA) (“Rich” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has submitted an investigational new drug (IND) application to conduct a Phase 2 clinical trial for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) with the U.S. Food and Drug Administration (FDA). Rich plans to initiate a multicenter, Phase 2 clinical study using RP-323 to treat AML and MDS patients. According to the American Cancer Society surveillance research group in 2014, it is estimated there will be 18,860 new cases of AML and 10,460 deaths from acute myeloid leukemia (AML) in the United States. Myelodysplastic syndrome is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow.
“We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS,” said Ben Chang, Chief Executive Officer. Rich submitted the IND for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS.
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) is a Biopharmaceutical Company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation and other blood related diseases. Rich Pharmaceuticals’ goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals’ primary development stage product candidate which is known as RP-323 is being designed to treat blood and cancer related diseases through none evasive outpatient facilities. Find out more at www.richpharmaceuticals.com.
Notice Regarding Forward-Looking Statements:
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
CONTACT: Ben Chang, CEO
9595 Wilshire Blvd., Suite 900
Beverly Hills, CA 90212
424-230-7001 EXT 105
(DAX) Recon Capital Launches the Only ETF to Track Germany’s
ETF Offers Highly Liquid Exposure and Low Cost to Blue-Chip German Stocks
Recon Capital, an investment firm and Exchange Traded Fund (ETF) provider, began trading the Recon Capital DAX Germany ETF (NASDAQ:DAX) on the NASDAQ Global Market today. The ETF provides investors with access to Germany, the Eurozone’s leading economy, with broad and highly liquid access to leading German blue-chip equities at a total annual operating expense ratio of 0.45%.
“Germany continues to be among the most promising and compelling economies in Europe. As the trusted measure of German blue-chips, DAX is one of the leading indices for financial products in the world. For the first time, it underlies ETFs in three key financial centers in Europe, Asia and now the United States,” said Hartmut Graf, chief executive officer, STOXX Limited. STOXX Ltd. is the marketing agent for the indices of Deutsche Börse AG and SIX, including the DAX and SMI indices.
DAX measures the development of the 30 largest and most liquid companies on the German equities market and represents around 80 percent of the market capitalization in Germany. It currently serves as the basis for more than 135,000 financial products and is one of the largest underlyings for derivatives globally.
“Germany is the locomotive of Europe and, with the Recon Capital DAX Germany ETF, we are giving U.S. investors access to the German equity market which proved to be comparably robust in displaying higher returns and lower volatility levels than most of its European counterparts,” said Garrett Paolella, CEO of Recon Capital. “Recon Capital focuses on using its investment expertise and operational infrastructure to deliver market-driven, value-added products that meet the evolving needs of global investors.”
About Recon Capital Partners:
Recon Capital Partners, LLC is an SEC registered investment adviser headquartered in Greenwich, Connecticut. Recon Capital provides better investment solutions for institutional investors, financial professionals, and individual investors in a liquid, transparent, and cost effective manner. Recon deploys its strategies through several formats including its exchange traded fund platform. For more information, visit http://www.reconfunds.com and www.reconcapitalpartners.com.
About Deutsche Börse
Deutsche Börse is one of the world’s leading data and technology service providers for the securities industry with a product and service offering for issuers, investors, intermediaries and data vendors. The Group covers the entire value chain from trading, through clearing, to settlement and securities custody. Deutsche Börse Market Data + Services encompasses the Group’s extensive market data offering and external technology and connectivity services. The product and service range includes real-time and historical data from the Group’s trading venues Eurex and Xetra as well as from cooperation partners. It also includes exclusive trading signals independent of its platforms such as economic indicators or macroeconomic news, reference data for more than 1,000,000 securities, approximately 10,500 indices including the STOXX and DAX index families, superior capital market infrastructure, and reliable connectivity services.
About Nasdaq:
Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.
Risk considerations
Please consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. A prospectus with this and other information about the Fund is available at www.ReconFunds.com or by calling 203-900-1400. The prospectus should be read carefully before investing.
The Recon Capital DAX Germany ETF (the “Fund”) is registered with the U.S. Securities and Exchange Commission as a non-diversified, management investment company, pursuant to the Investment Company Act of 1940. An investment in the Fund is subject to risk, including the loss of principal amount invested. There is no guarantee the Fund will achieve its investment objective. The Fund’s shares may be more volatile than the performance of a broadly diversified portfolio. The Fund is not by itself a complete or balanced investment program.
Shares of ETFs are bought and sold at market price (not net asset value (NAV)) and can be acquired or redeemed directly from a fund at NAV in Creation Units only. Brokerage commissions will reduce returns. Market returns are based upon the midpoint of the bid/ask spread at 4:00 p.m. eastern time (when NAV is normally determined for most ETFs) and do not represent the returns you would receive if you traded shares at other times.
Market forces may result in shares trading at a significant premium or discount to NAV. Although the shares are currently listed on an exchange, there can be no assurance that an active trading market for the shares will develop or be maintained.
The Fund’s performance is expected to be closely tied to social, political, and economic conditions within Europe and to be more volatile than the performance of more geographically diversified funds. An investment in European securities can be adversely affected by a variety of factors, among which are: restrictions on inflation rates, deficits, interest rates, debt levels and fiscal and monetary controls imposed by the European Union or European Monetary Union; historically high unemployment and significant debt problems in certain European nations; recently volatility in European financial markets due to concerns about economic downturns or rising government debt levels. Currently, a significant portion of the Index is allocated to securities of companies in France, Germany and Spain.
Recent events have adversely affected the exchange rate of the euro and may continue to significantly affect every country in Europe, including countries that do not use the euro. Changes in currency exchange rates and the relative value of non-U.S. currencies will affect the value of the Fund’s investment and the value of your Fund Shares. Because the Fund’s NAV is determined in U.S. dollars, the Funds NAV could decline if the currency of the non-U.S. market in which the Fund invests depreciates against the U.S. dollar, even if the value of the Fund’s holdings, measured in the foreign currency, increases.
The DAX Index and its related trademarks are proprietary to STOXX Limited. The DAX Index and the related trademarks have been licensed for certain purposes by Recon Capital. The Recon Capital DAX Germany ETF is not sponsored, sold, endorsed or promoted by STOXX Limited.
# # #
Recon Capital and Recon Capital Partners are registered with the U.S. Patent and Trademark Office, and may be registered or pending registration in other countries. All other trademarks or registered trademarks are the property of their respective owners.
(BFRE) Receives Unprecedented Export-Import Bank of China Letter of Intent
BlueFire’s Mississippi Fulton Project Paves the Way for Other U.S./China Renewable Energy Projects
IRVINE, Calif., Oct. 23, 2014 — BlueFire Renewables, Inc. (OTC:BFRE), a company focused on changing the world’s transportation fuel paradigm through the production of renewable fuels, announced that it has received a Letter of Intent from The Export Import Bank of China (China EXIM) to provide up to $270 million in debt financing for its bio-energy project in Fulton, Mississippi.
China EXIM’s interest in providing substantial financing to BlueFire is unprecedented and significant for the U.S. renewable energy sector and for U.S. renewable energy small businesses. Particularly in the capital-intensive energy industry, small businesses like BlueFire struggle to access capital amidst tightening credit markets in the U.S. since the financial crisis beginning in 2009.
“This is a significant feat, not just for BlueFire as it also provides a model for the U.S. small business community because it is a strong indication of China’s commitment to support and fund U.S. renewable energy technologies to improve the environment and build a strong foundation for cooperation between China and the U.S. in the field of renewable energy,” stated Arnold Klann, CEO of BlueFire Renewables, Inc.
“There are significant opportunities for replicating the BlueFire Fulton size or larger facilities in China and the U.S. to deal with problematic agricultural and urban waste currently being burned or buried,” Klann said. “Debt financing has been the most difficult part of the financing to obtain for the cellulosic biofuels industry. BlueFire’s business model and relationships with China EXIM will set the standard for future debt financing arrangements and could be the spark that leads to the more beneficial use of cellulosic wastes in the bio-fuels industry in the U.S. and China. We are cracking the code when it comes to striking a win-win business deal for China, the U.S. and energy consumers.”
Klann said that BlueFire has been working with China EXIM in response to the China Strategic and Economic Dialogue with the U.S., which encourages U.S./China cooperation in the renewable energy field. Due to the difficulty in obtaining financing for capital-intensive energy projects, many renewable energy projects do not get past the pilot phase and into the full commercial development stage. Dozens of renewable energy projects in the U.S. are languishing because of the debt-financing problem and the BlueFire solution could be the path to commercialization for many of these projects.
Because Loan Guarantee programs offered by U.S. Federal agencies (the Department of Energy and the Department of Agriculture) were not structured for small businesses, the BlueFire/China EXIM framework with major Chinese companies will open the door for more businesses in the U.S. to finance and build projects, not only in the U.S., but in China.
The Letter of Intent continues the international collaboration between U.S. and China initiated by BlueFire. “Combining the already announced engineering and project management contract with China Three Gorges, which is China’s largest utility, and now the addition of funding intended by the China EXIM Bank, both countries can work on the sustainable production of renewable fuels and chemicals while promoting jobs and the use of domestic and readily available biomass resources,” said Klann.
The companies will continue to work together to complete the standard due diligence procedures of the China EXIM bank and meet all credit criteria and condition precedent to reach definitive agreements in order to complete the financing as soon as possible. Once completed, China Three Gorges Corporation and its U.S. subcontractors will begin construction of the Fulton Project.
The Fulton, MS project will allow BlueFire to utilize green and wood wastes available in the region as feedstock for the ethanol plant that is designed to produce approximately 19-million gallons of ethanol per year.
About BlueFire Renewables, Inc.
BlueFire Renewables, Inc. was established to deploy the Arkenol patented and proven Concentrated Acid Hydrolysis Technology Process for the profitable conversion of cellulosic waste materials (“Green Waste”) to renewable fuel sources. BlueFire has demonstrated production of Biofuels from urban trash (post-sorted MSW), rice and wheat straws, wood waste and other agricultural residues.
BlueFire was awarded a grant totaling $88 million under the American Recovery and Reinvestment Act in December of 2009. BlueFire’s biorefineries will be located near markets with high demand for ethanol and will use locally available biomass. This should dramatically reduce delivery costs and increase biofuel supplies, while providing a unique waste processing technology to help America’s cities better manage the increasing problem of overflowing landfills. For more information, please visit www.BFREINC.com.
About The Export-Import Bank of China
The Export-Import Bank of China is one of three institutional banks in China chartered to implement the state policies in industry, foreign trade, diplomacy, the economy, and provide policy financial support so as to promote the export of Chinese products and services. It was established in 1994 and has a focus to promote foreign trade and investment as well as development assistance through concessional funding and other types of financing. Its main areas of business are energy, infrastructure, telecom, mining, and industrial sectors.
Forward-Looking Statements
Statements about BlueFire Renewables expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. BlueFire’s actual results could differ materially from expected results.
This press release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). BlueFire Renewables, Inc. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” or “anticipates,” and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful development and deployment of ethanol production facility or facilities, impact of the company’s expansion plan, new business development success, future financial results, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks and other factors are detailed in the Company’s regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company’s control. Forward-looking statements speak only as to the date they are made and BlueFire Renewables, Inc. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
CONTACT: Company Contact:
Richard Klann
BlueFire Renewables, Inc.
rgklann@bfreinc.com
949.588.3767, ext. 411
(NEWT) Small Business Economy Continues To Grow Modestly
Newtek, The Small Business Authority®, Releases September 2014 SB Authority Index
NEW YORK, Oct. 23, 2014 — Newtek Business Services, Inc. NASDAQ: NEWT, The Small Business Authority®, announced today the release of the SB Authority Index of small business indicators for September 2014 which reached 129.17 points. The Russell Microcap Index, new entity formation and retail sales led the increase. The SB Authority Index is up 0.28% from August 2014. On a year-over-year comparison, the SB Authority Index is up 5.88%.
Barry Sloane, Chairman, President and CEO of The Small Business Authority® commented, “Another tepid increase for the small business economy in the September Index as we are experiencing a roller coaster ride in the coastal markets. The Russell Micro-Cap Index and interest rates are experiencing extreme volatility, coupled with worldwide events such as ISIS and Ebola threatening the small business economy. These events tend to lead to the type of uncertainty that slows the small business economy and creates hesitancy amongst independent business owners.”
About Newtek Business Services, Inc.
Newtek Business Services, Inc., The Small Business Authority®, is the Authority for the small- and medium-sized business (SMB) market providing a wide range of business services and financial products under the Newtek® brand. Since 1999, Newtek has provided state-of-the-art, cost-efficient products and services and efficient business strategies to over 100,000 business accounts across all 50 States to help them grow their sales, control their expenses and reduce their risk.
Newtek’s products and services include: The Newtek Advantage™, Electronic Payment Processing, Managed Technology Solutions (Cloud Computing), eCommerce, Business Lending, Insurance Services, Web Services, Data Backup, Storage and Retrieval, Accounts Receivable Financing, Payroll.
The Small Business Authority® is a registered trade mark of Newtek Business Services, Inc., and neither are a part of or endorsed by the U.S. Small Business Administration.
Note Regarding Forward Looking Statements
Statements in this press release including statements regarding Newtek’s beliefs, expectations, intentions or strategies for the future, may be “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from the plans, intentions and expectations reflected in or suggested by the forward-looking statements. Such risks and uncertainties include, among others, intensified competition, operating problems and their impact on revenues and profit margins, anticipated future business strategies and financial performance, anticipated future number of customers, business prospects, legislative developments and similar matters. Risk factors, cautionary statements and other conditions, which could cause Newtek’s actual results to differ from management’s current expectations, are contained in Newtek’s filings with the Securities and Exchange Commission and available through http://www.sec.gov.
FROM:
Newtek Business Services, Inc.
http://www.thesba.com
Contact: Simrita Singh
Telephone: (212) 356-9566 / ssingh@thesba.com
Investor Relations
Contact: Jayne Cavuoto
Telephone: (212) 273-8179 / jcavuoto@thesba.com
Contact: Brett Maas
Telephone: (646) 536-7331 / brett@haydenir.com
TraderPower Featured Companies
Top Small Cap Market News
- $SOBR InvestorNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Closes on $8.2M Private Placement
- $CLNN InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
Recent Posts
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
Recent Comments
Archives
- October 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009